Jinte Middeldorp

Dr. Jinte Middeldorp

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Glia
Verified
Journal Article
Open access
PDF file
TSTamar Smit
Tamar Smit
NDNatasja A. C. Deshayes
Natasja A. C. Deshayes
DBDavid R. R Borchelt
David R. R Borchelt
WKWillem Kamphuis
Willem Kamphuis
JMJinte Middeldorp
Jinte Middeldorp
Elly HolElly Hol
Elly Hol
Astrocytes regulate synaptic communication and are essential for proper brain functioning. In Alzheimer's disease (AD) astrocytes become reactive, which is characterized by an increased expression of intermediate filament proteins and cellular hypertrophy. Reactive astrocytes are found in close association with amyloid‐beta (Aβ) deposits. Synaptic communication and neuronal network function could be directly modulated by reactive astrocytes, potentially contributing to cognitive decline in AD. In this review, we focus on reactive astrocytes as treatment targets in AD in the APPswePS1dE9 AD mouse model, a widely used model to study amyloidosis and gliosis. We first give an overview of the model; that is, how it was generated, which cells express the transgenes, and the effect of its genetic background on Aβ pathology. Subsequently, to determine whether modifying reactive astrocytes in AD could influence pathogenesis and cognition, we review studies using this mouse model in which interventions were directly targeted at reactive astrocytes or had an indirect effect on reactive astrocytes. Overall, studies specifically targeting astrocytes to reduce astrogliosis showed beneficial effects on cognition, which indicates that targeting astrocytes should be included in developing novel therapies for AD.

8 April 2022 in Viruses
Verified
Journal Article
Open access
PDF file
IPIngrid H. C. H. M. Helena Philippens
Ingrid H. C. H. M. Helena Philippens
KBKinga Böszörményi
Kinga Böszörményi
JWJacqueline A. M. Wubben
Jacqueline A. M. Wubben
ZFZahra C. Fagrouch
Zahra C. Fagrouch
NDNikki van Driel
Nikki van Driel
BVBabs E Verstrepen
Babs E Verstrepen
SARS-CoV-2 causes acute respiratory disease, but many patients also experience neurological complications. Neuropathological changes with pronounced neuroinflammation have been described in individuals after lethal COVID-19, as well as in the CSF of hospitalized patients with neurological complications. To assess whether neuropathological changes can occur after a SARS-CoV-2 infection, leading to mild-to-moderate disease, we investigated the brains of four rhesus and four cynomolgus macaques after pulmonary disease and without overt clinical symptoms. Postmortem analysis demonstrated the infiltration of T-cells and activated microglia in the parenchyma of all infected animals, even in the absence of viral antigen or RNA. Moreover, intracellular α-synuclein aggregates were found in the brains of both macaque species. The heterogeneity of these manifestations in the brains indicates the virus’ neuropathological potential and should be considered a warning for long-term health risks, following SARS-CoV-2 infection.

16 June 2022 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
LHLianne A. Hulshof
Lianne A. Hulshof
DNDanny van Nuijs
Danny van Nuijs
EHElly M. Hol
Elly M. Hol
JMJinte Middeldorp
Jinte Middeldorp
Alzheimer's disease (AD) is the most common cause of dementia, affecting 35 million people worldwide. One pathological feature of progressing AD is the loss of synapses. This is the strongest correlate of cognitive decline. Astrocytes, as an essential part of the tripartite synapse, play a role in synapse formation, maintenance, and elimination. During AD, astrocytes get a reactive phenotype with an altered gene expression profile and changed function compared to healthy astrocytes. This process likely affects their interaction with synapses. This systematic review aims to provide an overview of the scientific literature including information on how astrocytes affect synapse formation and elimination in the brain of AD patients and in animal models of the disease. We review molecular and cellular changes in AD astrocytes and conclude that these predominantly result in lower synapse numbers, indicative of decreased synapse support or even synaptotoxicity, or increased elimination, resulting in synapse loss, and consequential cognitive decline, as associated with AD. Preventing AD induced changes in astrocytes might therefore be a potential therapeutic target for dementia.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=148278, identifier [CRD148278].

22 February 2023 in Frontiers in Aging
Verified
Journal Article
Open access
LCL. Coenen
L. Coenen
BLB. Lehallier
B. Lehallier
HVH. E. de Vries
H. E. de Vries
JMJinte Middeldorp
Jinte Middeldorp
Aging associates with an increased susceptibility for disease and decreased quality of life. To date, processes underlying aging are still not well understood, leading to limited interventions with unknown mechanisms to promote healthy aging. Previous research suggests that changes in the blood proteome are reflective of age-associated phenotypes such as frailty. Moreover, experimentally induced changes in the blood proteome composition can accelerate or decelerate underlying aging processes. The aim of this study is to identify a set of proteins in the human plasma associated with aging by integration of the data of four independent, large-scaled datasets using the aptamer-based SomaScan platform on the human aging plasma proteome. Using this approach, we identified a set of 273 plasma proteins significantly associated with aging (aging proteins, APs) across these cohorts consisting of healthy individuals and individuals with comorbidities and highlight their biological functions. We validated the age-associated effects in an independent study using a centenarian population, showing highly concordant effects. Our results suggest that APs are more associated to diseases than other plasma proteins. Plasma levels of APs can predict chronological age, and a reduced selection of 15 APs can still predict individuals’ age accurately, highlighting their potential as biomarkers of aging processes. Furthermore, we show that individuals presenting accelerated or decelerated aging based on their plasma proteome, respectively have a more aged or younger systemic environment. These results provide novel insights in the understanding of the aging process and its underlying mechanisms and highlight potential modulators contributing to healthy aging.

8 February 2021 in Neurochemical Research
Verified
Journal Article
Open access
PDF file
MVMarloes Verkerke
Marloes Verkerke
Elly HolElly Hol
Elly Hol
JMJinte Middeldorp
Jinte Middeldorp
Ageing is the greatest risk factor for dementia, although physiological ageing by itself does not lead to cognitive decline. In addition to ageing, APOE ε4 is genetically the strongest risk factor for Alzheimer’s disease and is highly expressed in astrocytes. There are indications that human astrocytes change with age and upon expression of APOE4. As these glial cells maintain water and ion homeostasis in the brain and regulate neuronal transmission, it is likely that age- and APOE4-related changes in astrocytes have a major impact on brain functioning and play a role in age-related diseases. In this review, we will discuss the molecular and morphological changes of human astrocytes in ageing and the contribution of APOE4. We conclude this review with a discussion on technical issues, innovations, and future perspectives on how to gain more knowledge on astrocytes in the human ageing brain.

12 February 2022 in Neurobiology of Aging
Verified
Journal Article
Open access
LHLianne A. Hulshof
Lianne A. Hulshof
LFLeon A. Frajmund
Leon A. Frajmund
DNDanny van Nuijs
Danny van Nuijs
DHDenise C.N. van der Heijden
Denise C.N. van der Heijden
JMJinte Middeldorp
Jinte Middeldorp
Elly HolElly Hol
Elly Hol
Alzheimer's disease (AD) is the most common cause of dementia. Despite many years of research, very limited treatment options are available. Here we aim to establish a well-defined learning and memory performance test for an AD mouse model, which can be used in future studies to evaluate the effect of novel drugs, treatments, and interventions. We exposed 9-month-old APPswe/PSEN1dE9 mice to a battery of memory tests to determine which test is best suited to study memory deficits in this specific AD mouse model. Since in more recent years it has become clear that there are sex-dependent differences in AD pathology, we also assessed differences in performance between male and female mice. From our test battery, we conclude that the Barnes maze task, which spans multiple days, is better suited to study subtle learning and memory deficits in 9-month-old APPswe/PS1dE9 mice, than the 2 trial T-maze and Fear conditioning task. This test revealed deficits in both spatial memory and cognitive flexibility in the APPswe/PS1dE9 mice compared to wildtype littermates. Furthermore, we conclude that there are no sex dependent memory deficit differences in this AD mouse model at this age.